Clorox

As of September 30, 2025, cash and cash equivalents were 166 million, notes and loans payable 218 million and long‑term debt 2.485 billion. Interest coverage is robust (FY2025 EBIT around 1.16 billion vs 88 million interest expense) and credit ratings remain investment grade (S&P BBB+, Moody’s Baa1).

The company has a 1.2 billion revolver maturing 2030. Known upcoming cash use is the January 2026 purchase of P&G’s 20 percent Glad stake, shown in material cash requirements at 476 million. We estimate TTM FCF of ~636 million through Q1 FY2026, implying net debt at roughly 4x FCF, acceptable for a stable staple with strong visibility.

The 2023 cyberattack has transitioned from a liquidity risk to resolved operations and insurance recoveries in FY2025. Overall, the balance sheet is sound with adequate flexibility to fund ERP and the Glad obligation while maintaining the dividend.